DOCSLIB.ORG

Actualización En El Manejo Clínico De La Anticoncepción Hormonal, Intrauterina Y De Urgencia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Actualización En El Manejo Clínico De La Anticoncepción Hormonal, Intrauterina Y De Urgencia CONFERENCIA DE CONSENSO ACTUALIZACIÓN EN EL MANEJO CLÍNICO DE LA ANTICONCEPCIÓN HORMONAL, INTRAUTERINA Y DE URGENCIA 26 y 27 de Noviembre de 2011, Madrid SOCIEDAD ESPAÑOLA DE CONTRACEPCIÓN CONFERENCIA DE CONSENSO ACTUALIZACIÓN EN EL MANEJO CLÍNICO DE LA ANTICONCEPCIÓN HORMONAL, INTRAUTERINA Y DE URGENCIA Derecho de copia reservada a la SEC Prohibido la reproducción total o parcial sin autorización de la SEC 2 PRESENTACIÓN Las Conferencias de Consenso de la Sociedad Española de Contracepción (SEC) constituyen una referencia en la actualización de la evidencia científica que permite el manejo adecuado y correcto de los diferentes métodos anticonceptivos por parte de los profesionales sanitarios. Esta nueva Conferencia de Consenso es el resultado de la experiencia adquirida anteriormente en el desarrollo de este tipo de reuniones y del deseo de la SEC de continuar en la línea del análisis científico que permita la elaboración de recomendaciones prácticas para el desarrollo de nuestra actividad. Tenemos que agradecer a todos los participantes el esfuerzo realizado para la consecución de los resultados que aquí presentamos que supone el trabajo de muchos profesionales. Prof. J. Calaf Alsina Dr. E. Pérez Campos Dra. E. de la Viuda Presidente del Jurado Coordinador de la CdC Presidenta de la SEC 3 4 ÍNDICE 1. Planteamiento de la Conferencia de Consenso (CdC)................................... 7 1.1. Introducción.......................................................................................................................... 8 1.2. Objetivos............................................................................................................................... 8 2. Desarrollo de la CdC........................................................................................... 9 2.1. Composición de la CdC...................................................................................................... 10 2.2. Función del Jurado.............................................................................................................. 12 2.3. Función de los Expertos...................................................................................................... 12 2.4. Programa de la Conferencia............................................................................................... 13 3. Ponencias de Expertos........................................................................................ 17 4. Recomendaciones Definitivas............................................................................ 203 5. Informe del Grupo de la Revisión Bibliográfica............................................... 213 5.1. Abreviaciones y acrónimos................................................................................................. 214 5.2. Metodología......................................................................................................................... 215 5.3. Resúmenes de la evidencia................................................................................................ 220 5.4. Anexos................................................................................................................................... 327 5 6 PLANTEAMIENTOS DE LA CAPÍTULO CONFERENCIA DE CONSENSO (CdC) 1 1.1. Introducción .........................................................................................8 1.2. Objetivos.................................................................................................8 1.1. INTRODUCCIÓN Se detectó, por parte de la Junta Directiva de la Sociedad Española de Contracepción (SEC), la conveniencia de examinar, a la luz de la Medicina Basada en laEvidencia, las novedades que en materia de Anticoncepción Hormonal, intrauterina y de Urgencia se han venido produciendo desde el último Consenso celebrado por la SEC en 2005. Para ello se ha recurrido de nuevo a la metodología de la Conferencia de Consenso (CdC) que, como es sabido, consiste en la redacción de unas recomendaciones por parte de un Jurado cualificado y multidisciplinar. Las recomendaciones se elaboran tras escuchar la opinión de los Expertos quienes presentan sus informes sintetizando los conocimientos existentes en base a la mejor Evidencia Científica disponible, proporcionada tras el estudio exhaustivo de la misma. La CdC es una conferencia científica en la que los expertos exponen sus trabajos. Sigue a esta exposición un debate democrático, en el que cada participante (expertos, jurado y público invitado) puede expresar su opinión. Se concluye con una resolución “judicial”, en la que el Jurado, de composición multidisciplinar y multiprofesional, establece las recomendaciones a puerta cerrada de manera independiente y objetiva. Existe la necesidad de actualizar los conocimientos y los consensos científicos sobre los anticonceptivos hormonales. 1.2. OBJETIVOS El objetivo de la CdC fue la actualización de los criterios sobre el manejo clínico de la anticocepción hormonal regular intrauterina y de urgencia, examinando las diversas pautas de administración, vías de aplicación y nuevos componentes de los mismos. 8 CAPÍTULO DESARROLLO DE LA (CdC) 2 2.1. Composición de la CdC................................................................... 10 2.2. Función del Jurado........................................................................... 12 2.3. Función de los Expertos................................................................... 12 2.4. Programa de la Conferencia............................................................ 13 2.1. COMPOSICIÓN DE LA CDC Promotor: Sociedad Española de Contracepción Comité Organizador: Coordinador: Dr. D. Ezequiel Pérez Campos Junta Directiva: Dra. Dña. Esther de la Viuda García PRESIDENTA Dra. Dña. Macarena Quesada VICEPRESIDENTA Dra. Dña. Mª J. Alonso Llamazares SECRETARIA Dra. Dña. Nuria Parera Junyent VICESECRETARIA Dr. D. José Vicente González Navarro TESORERO Dr. D. José Ramón Serrano Navarro VICETESORERO Dra. Dña. Mercedes Martínez Benavides VOCALES Dra. Dña. Mª Ángeles Gómez Martínez VOCALES Jurado: Presidente del Jurado: Prof. D. Joaquim Calaf Alsina Jurado Dra. Dña. Mercedes Abizanda Barcelona Dr. D. Javier Martínez Salmeán Madrid Dra. Dña. Mª Jesús Alonso Llamazares Málaga Dra. Dña. Fca. Martínez San Andrés Barcelona Prof. D. Joaquim Calaf Alsina Barcelona Dra. Dña. Dolores Montero Madrid Dra. Dña. Carmen Coll Capdevila Barcelona Dr. D. Javier Rodríguez Martorell Sevilla Dra. Dña. Esther de la Viuda García Madrid Dra. Dña. Merce Roque Moreno Barcelona Dr. D. José Luis Doval Conde Orense Dra. Dña. Ana Saavedra Ruíz Granada Dr. D. José Luis Dueñas Díez Sevilla Dr. D. Luis Enrique Sánchez Madrid Dr. D. Iñaki Lete Lasa Vitoria Dra. Dña. Isabel Serrano Fuster Madrid Dr. D. Eduardo A. López Arregui Bilbao Dr. D. Jose R. Serrano Navarro Bilbao Expertos Dra. Dña. Mª Angels Avecilla Palau Barcelona Dra. Dña. Inmaculada Parra Ribes Sueca Dr. D. Sergio Haimovich Segal Barcelona Dra. Dña. Isabel María Ramírez Polo Cádiz Dr. D. Roberto Lertxundi Barañano Bilbao Dr. D. Alberto Salamanca Ballesteros Granada Dra. Dña. Mª Paloma Lobo Abascal Madrid Dr. D. Ivan Solà Barcelona Dr. D. N. Mendoza Ladrón de Guevara Granada Moderadores: Dra. Dña. M. Martínez Benavides Sevilla Dr. D. Rafael Sánchez Borrego Barcelona Dra. Dña. Nuria Parera Junyent Barcelona Dra. Dña. Mª.J. Cancelo Hidalgo Guadalajara 10 Grupo de Revisión Bibliográfica: Iberoamerican Cochrane Centre Director: Dr. Iván Solá Público Participante: Dra. Dña. Magdalena Balaguer Fabuel Valencia Dra. Dña. Mª Pilar Obón García Valencia Dr. D. Santiago Barambio Bermúdez Barcelona Dra. Dña. Silvia Adriana Oizerovich Argentina Dr. D. V.Barragán Gómez Coronado Cáceres Dr. D. Santiago Palacios Gil-Antuñano Madrid Dr. D. Sergio Bernabeu Pérez Alicante Dr. D. Pedro Peña Coello Málaga Dra. Dña. Isolina Bonacho Paniagua La Coruña Dr. D. Jorge Perpiñá Cano Valencia Dra. Dña. Ana Isabel Casasus Mier Bilbao Dra. Dña. Mª Dolores Porras Triano Málaga Dra. Dña. Mª José Coco Alonso Cádiz Dra. Dña. Neus Prat Puigpelat Barcelona Dra. Dña. Marta Correa Rancel S.C. de Tenerife Dra. Dña. Cristina Puig Barcelona Dra. Dña. I.De las Casas Vilchez Almería Dra. Dña. Angels Ramírez Hidalgo Barcelona Dra. Dña. Ana Isabel Etxebarría Ugarte Durango Dra. Dña. Sira Repolles Lasheras Zaragoza Dra. Dña. Ana Isabel Fernández Quintá Madrid Dr. D. Modesto Rey Novoa Burgos Dr. D. Joaquín García Cervera Valencia Dr. D. Javier Robledo Roque Valencia Dr. D. Esteban González Mirasol Albacete Dra. Dña. Mª J. Rodríguez Domingo Barcelona Dr. D. Salvador Gotor Montoro Málaga Dra. Dña. Mª José Rodríguez Jiménez Madrid Dra. Dña. María Guerrero Ibáñez Burgos Dra. Dña. Elena Rodríguez Ortiz Sevilla Dr. D. José Gutiérrez Ales Sevilla Dra. Dña. Rosa Ros Rahola Barcelona Dr. D. Francisco Javier Haya Palazuelos Getafe Dra. Dña. Marta Salvador Osuna Madrid Dra. Dña. Azucena Llopis Pérez Mérida Dr. D. Pablo Sánchez-Valverde Visus Pamplona Dra. Dña. Manuela López López Madrid Dra. Dña. Raquel Senosiain Echarte Barcelona Dra. Dña. José María Marí Juan Valencia Dra. Dña. Diana Sojo Guttero Madrid Dr. D. Fernando Marín Rodríguez S.C. de Tenerife Dr. D. Manuel Sosa Marrero Las Palmas de G.C. Dra. Dña. María Martín Gómez Guadalajara Dra. Dña. María Suárez Mayor Barcelona Dr. D. Sagrario Mateu Sanchis Madrid Dr. D. Javier Valdes Pons Vigo Dra. Dña. Hildegard Mausbach Reisen Barcelona Dr. D. Eduardo Yáñez González Vigo Dr. D. Joaquín Moliner Tena Castellón 11 2.2. FUNCIÓN DEL JURADO Antes de la Conferencia: - Reunión preparatoria para fijar las modalidades de trabajo
Load more

Recommended publications
  • Everything You Need to Know About the Contraceptive Implant FDA Approval Means US Women Now Have a Progestin-Only Implant Among Their Birth Control Options
    OBGM_0906_Darney.final 8/18/06 11:36 AM Page 50 OBGMANAGEMENT Everything you need to know about the contraceptive implant FDA approval means US women now have a progestin-only implant among their birth control options n July 17, the US Food and Drug or even monthly action on the part of the Administration (FDA) approved user, it is well-suited for: Philip D. Darney, MD, MSc what may be the most effective • Women who wish to or need Professor and Chief, Department O of Obstetrics, Gynecology, and hormonal contraceptive ever developed, a to avoid estrogen Reproductive Sciences, University single-rod implant that goes by the trade • Teens who find adherence to a of California-San Francisco, name Implanon. The implant contains 68 contraceptive regimen difficult San Francisco General Hospital ® Dowden Health Media mg of etonogestrel (ENG), the active • Healthy adult women who desire metabolite of desogestrel, in a membrane long-term protection ofCopyright ethylene vinylFor acetate. personal In clinical usetrials only• Women who are breastfeeding involving 20,648 cycles of exposure, only 6 pregnancies occurred, for a cumulative 1 Pearl Index of 0.38 per 100 woman-years. ❚ IN THIS ARTICLE This article reviews: Pros and cons • the 2 contraceptive mechanisms Advantages include: ❙ How the • indications and patient selection • Cost. A study2 of 15 contraceptive progestin-only • pharmacology, safety, adverse effects methods found the implant cost-effec- implant prevents • patient satisfaction and discontinua- tive compared to short-acting methods, tion rates provided it was used long-term. As of fertilization • insertion and removal press time, the manufacturer had not Page 52 • key points of patient counseling released the price.
    [Show full text]
  • ESTROSTEP Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets*) *Ferrous Fumarate Tablets Are Not USP for Dissolution and Assay
    ESTROSTEP Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets*) *Ferrous fumarate tablets are not USP for dissolution and assay. ESTROSTEP® Fe (Each white triangular tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol; each white square tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; each white round tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol; each brown tablet contains 75 mg ferrous fumarate.) Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. DESCRIPTION ESTROSTEP® Fe is a graduated estrophasic oral contraceptive providing estrogen in a graduated sequence over a 21-day period with a constant dose of progestogen. ESTROSTEP Fe provides for a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each white triangle-shaped tablet contains 1 mg norethindrone acetate [(17 alpha)-17- (acetyloxy)-19-norpregna-4-en-20-yn-3-one] and 20 mcg ethinyl estradiol [(17 alpha)-19- norpregna-1,3,5(10)-trien-20-yne-3,17-diol]; each white square-shaped tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; and each white round tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each tablet also contains calcium stearate; lactose; microcrystalline cellulose; and starch. The structural formulas are as follows: Each brown tablet contains ferrous fumarate, mannitol, povidone, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, sucralose and spearmint flavor.
    [Show full text]
  • Emergency Contraception
    Need more information? State of Illinois This document provides some very basic information about emergency Illinois Department of Public Health contraception and how it works. If EC is something you want to know more about, ask the hospital emergency personnel about their policy on EC or ask the sexual assault advocate for assistance in getting this information. Local Support/Assistance: What You Should Know About Emergency Contraception For more information, contact ILLINOIS DEPARTMENT OF PUBLIC HEALTH 535 W. Jefferson St. Springfield, IL 62761 217-782-5750 Women’s Health-line 888-522-1282 TTY (hearing impaired use only) 800-547-0466 www.idph.state.il.us Developed by the Illinois Department of Public Health in cooperation with the Illinois Coalition Against Sexual Assault Printed by Authority of the State of Illinois IOCI 0041-1 Illinois law provides that victims of sexual assault are entitled to If I am already pregnant, medically and factually accurate information about emergency contra - ception (EC) when they receive emergency care in a hospital. Under will EC hurt the fetus? the Sexual Assault Survivors Emergency Treatment Act (410 ILCS There is no evidence that EC causes birth defects. However, there 70/2.2), Illinois hospitals are required to have a policy in place regarding have been no studies specific to taking birth control at this dosage. emergency contraception. Individual hospital protocols must ensure What is known is that babies born to women who continue taking that each victim of sexual assault will receive medically and factually birth control pills before finding out they are pregnant do not have accurate written and oral information about emergency contraception; higher rates of birth defects.
    [Show full text]
  • ARANELLE- Norethindrone and Ethinyl Estradiol Teva Pharmaceuticals USA, Inc
    ARANELLE- norethindrone and ethinyl estradiol Teva Pharmaceuticals USA, Inc. ---------- Aranelle®(norethindrone and ethinyl estradiol tablets USP) Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. DESCRIPTION Aranelle® 28-Day Regimen (norethindrone and ethinyl estradiol tablets USP) provides a continuous oral contraceptive regimen of 7 light yellow tablets, 9 white tablets, 5 more light yellow tablets, and then 7 peach tablets. Each light yellow tablet contains norethindrone, USP 0.5 mg and ethinyl estradiol, USP 0.035 mg, each white tablet contains norethindrone, USP 1 mg and ethinyl estradiol, USP 0.035 mg, and each peach tablet contains inert ingredients. Norethindrone, USP is a potent progestational agent with the chemical name 17- Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one. Ethinyl estradiol, USP is an estrogen with the chemical name 19-Nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol. Their structural formulae follow. Norethindrone, USP Ethinyl Estradiol, USP The light yellow tablet contains the following inactive ingredients, D&C yellow no. 10 aluminum lake, lactose monohydrate, magnesium stearate, and pregelatinized starch. The white tablet contains the following inactive ingredients, lactose monohydrate, magnesium stearate, and pregelatinized starch. The inactive peach tablets contain the following inactive ingredients, anhydrous lactose, FD&C yellow no. 6 aluminum lake, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotrophins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which may reduce the likelihood of implantation).
    [Show full text]
  • Contraceptive Implant
    your guide to the contraceptive implant Helping you choose the method of contraception that is best for you contraceptive implant contraceptivecontraceptive implant implant contraceptivecontraceptivecontraceptive contraceptive contraceptive contraceptiveimplantcontraceptive implant contraceptive contraceptivecontraceptive implant implantcontraceptive contraceptive contraceptivecontraceptivecontraceptive 2 3 How effective is an implant? The contraceptive How effective any contraceptive is depends on how old you are, how often you have sex and implant whether you follow the instructions. If 100 sexually active women don’t use any An implant is a small flexible rod that is placed contraception, 80 to 90 will become pregnant in just under your skin in your upper arm. It releases a year. a progestogen hormone similar to the natural The implant is over 99 per cent effective. Less progesterone that women produce in their than one woman in every 1,000 will get pregnant ovaries and works for up to three years. over three years. The implant is a method of long- acting reversible contraception (LARC). All LARC is very effective because while it is being used you do not have to remember to take or use contraception. How does an implant work? The main way it works is to stop your ovaries releasing an egg each month (ovulation). It also: O Thickens the mucus from your cervix. This makes it difficult for sperm to move through your cervix and reach an egg. Contents How effective is an implant? .........................................................3
    [Show full text]
  • Contraceptive Implant (Nexplanon) PATIENT EDUCATION SERIES
    Contraceptive Implant (Nexplanon) PATIENT EDUCATION SERIES What is Nexplanon? Nexaplon replaced the In studies, 1 out of 10 women stopped using birth control implant Implanon in 2010. Birth Implanon because of bleeding changes. control implants have been used worldwide for close • 3.6% of clinical study participants experienced to 20 years. It is a flexible plastic rod about the size implant site complications such as pain, or hema- of a cardboard matchstick which is inserted just toma, redness or swelling at the time of implan- under the skin on the inner side of the upper arm. tation. Removal complications occurred in 1.7% It contains etonogestrel (a form of progesterone) of study participants and included broken or which is released over a three year period to provide damaged implant, difficult localization and slight very effective protection against pregnancy. Inser- movement. There is a slight risk of scarring from tion requires a local anesthetic and only takes a few insertion or removal. minutes. • Side effects besides irregular bleeding can How does Nexplanon work? include mood swings, weight gain, breast tender- Nexplanon works by changing the cervical mucus ness, headache or acne. Other side effects that (making it harder for sperm to swim through) have been reported include dizziness, stomach and decreasing tubal motility, thus inhibiting pain, hair loss, painful periods, nervousness, fertilization. To a lesser degree it also make the back pain or nausea. Rarely extra hair on body, lining of the uterus less receptive to implantation trouble using contact lenses and spotty darken- and can inhibit ovulation. ing of skin has occurred.
    [Show full text]
  • Emergency Contraception
    AQ FREQUENTLY ASKED QUESTIONS FAQ114 fCONTRACEPTION Emergency Contraception • What is emergency contraception? • How does emergency contraception work? • What are the different types of emergency contraception? • What is the most effective form of emergency contraception? • How does the copper intrauterine device work? • What are the possible side effects of using the copper intrauterine device? • How do emergency contraception pills work? • How often can I use emergency contraception pills? • What are the possible side effects of taking emergency contraception pills? • Is there anything that decreases the effectiveness of emergency contraception pills? • How can I get emergency contraception as soon as possible? • How do I start or resume using a birth control method after taking emergency contraception pills? • Do I need follow-up care after using emergency contraception? • Glossary What is emergency contraception? Emergency contraception (EC) reduces the chance of pregnancy after unprotected sexual intercourse. Common situations in which EC could be used include forgetting to take several birth control pills in a row, having a condom break or slip off, or not using a birth control method during sex. It also can be used after a woman has been raped. How does emergency contraception work? Using EC does not cause an abortion. An abortion ends an existing pregnancy. EC prevents pregnancy from occurring. EC must be used soon after unprotected sexual intercourse to be effective. It does not work if pregnancy has already occurred. What are the different types of emergency contraception? There are two main types of EC: 1) the copper intrauterine device (IUD) and 2) EC pills. There are three types of EC pills: 1) ulipristal, 2) progestin-only pills, and 3) combined EC pills.
    [Show full text]
  • Information for the User Nexplanon® 68 Mg Implant for Subdermal Use
    Package leaflet: Information for the user Nexplanon® 68 mg implant for subdermal use Etonogestrel Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. Your doctor will give you a Patient Alert Card that contains important information you need to be aware of. Store the card in a safe place, and show it to your healthcare professional at any visits related to the use of your implant. What is in this leaflet 1. What Nexplanon is and what it is used for 2. What you need to know before you use Nexplanon 3. How to use Nexplanon 4. Possible side effects 5. How to store Nexplanon 6. Contents of the pack and other information 7. Information for the health care professional 1. What Nexplanon is and what it is used for Nexplanon is a contraceptive implant preloaded in a disposable applicator. Safety and efficacy have been established in women between 18 and 40 years of age. The implant is a small, soft, flexible, plastic rod, 4 cm in length and 2 mm in diameter, which contains 68 milligrams of the active substance, etonogestrel. The applicator allows the healthcare professional to insert the implant just under the skin of your upper arm. Etonogestrel is a synthetic female hormone resembling progesterone.
    [Show full text]
  • Emergency Contraception Krishna K
    POLICY STATEMENT Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of all Children Emergency Contraception Krishna K. Upadhya, MD, MPH, FAAP, COMMITTEE ON ADOLESCENCE Despite significant declines over the past 2 decades, the United States abstract continues to experience birth rates among teenagers that are significantly higher than other high-income nations. Use of emergency contraception (EC) within 120 hours after unprotected or underprotected intercourse can reduce the risk of pregnancy. Emergency contraceptive methods include oral Children’s National Health System, Washington, District of Columbia medications labeled and dedicated for use as EC by the US Food and Drug Policy statements from the American Academy of Pediatrics benefit Administration (ulipristal and levonorgestrel), the “off-label” use of combined from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American oral contraceptives, and insertion of a copper intrauterine device. Indications Academy of Pediatrics may not reflect the views of the liaisons or the for the use of EC include intercourse without use of contraception; condom organizations or government agencies that they represent. breakage or slippage; missed or late doses of contraceptives, including the Dr Upadhya was responsible for all aspects of revising and writing the policy statement with input from reviewers and the Board of Directors; oral contraceptive pill, contraceptive patch, contraceptive ring, and injectable she approves the final manuscript as submitted. contraception; vomiting after use of oral contraceptives; and sexual assault. The guidance in this statement does not indicate an exclusive course Our aim in this updated policy statement is to (1) educate pediatricians and of treatment or serve as a standard of medical care.
    [Show full text]
  • Emergency Contraception
    September 2018 | Fact Sheet Emergency Contraception Emergency contraception (EC), sometimes referred to as “the morning-after pill,” is a form of backup birth control that can be taken up to several days after unprotected intercourse or contraceptive failure and still prevent a pregnancy. In 1999, Plan B was the first oral product approved for use in the U.S. as an EC by the Food and Drug Administration (FDA). Since then, more EC products have been approved, and there has been debate over access to EC, particularly over-the-counter availability for teenagers. Many have confused EC with the “abortion pill,” but EC does not cause abortion, since it works by delaying or inhibiting ovulation and will not work if the woman is already pregnant. This fact sheet reviews the methods of EC, known mechanisms of action, women’s awareness of EC, and current national and state policies affecting EC access. WHAT IS EC? Emergency contraception is used as a back-up birth control method to prevent unintended pregnancy after sex in the event of unprotected sex, sexual assault, or a contraceptive failure, such as a condom breaking. There are several methods of EC that are available in the U.S. including progestin-based pills, ulipristal acetate, and copper IUDs (Table 1). Unlike the copper IUD, EC pills are not intended for use as a regular contraceptive method. ECs do not terminate a pregnancy. Table 1: Major Methods of Emergency Contraception (EC), Availability and Policy in the U.S. Timing after Brand Name Efficacya Availability in the U.S. intercourse One dose versions approved for Progestin-only pills—11 81 - 90% reduced pregnancy riskb Within 72 hours availability “over the counter” brandsC without age restrictions.
    [Show full text]
  • Contraception for Teens
    Contraception for Teens Dr. Julie Hakim, MD, FRCSC Assistant Professor, Pediatric Gynecology Texas Children’s Hospital NODISCLOSURES Adolescent Pregnancy in U.S. in adolescent girls 3 10 will become pregnant by age 20 The National Campaign to Prevent Teen and Unplanned Pregnancy, February 2011. http:// www.thenationalcampaign.org/resources/pdf/FastFacts_3in10.pdf Teenage Birth Rates for 15-19 Year Olds by State, 2014 U.S Teen Birth rate was 24.2 in 2014 Less Than 20 20.0 to 29.9 30.0 to 39.9 Use of Contraception at First Sex Among Males and Females Aged 15-19, by Age at First Sex: United States, 1988-2013 120 Total 99 100 93 17 and under 84 82 18-19 79 77 80 Percentage of male and female teenagers 60 aged 17 and under who used contraception at first sex was significantly lower than that of teenagers aged 18-19 40 (p < 0.05) SOURCE: 20 CDC/NCHS, National Survey of Family Growth, 1988 – 2013, 0 Male Female Why Aren’t Adolescents Using Contraception? ! "Adolescence: ! " Early adolescence: present oriented, impulsive ! " Middle adolescence: omnipotent, invincible ! "Spontaneous ! "Pressure ! "Ambivalence about pregnancy “I can handle it” ! "Inadequate information “I can’t get pregnant anyways..” ! "Inadequate confidential care How Teens Get Their Information ! "Friends or relatives ! "Whatever is accessible ! "Media – FB, Instagram, Snapchat ! "Fear of side effects ! "Physician recommendation Non Hormonal & Barrier ! " Copper IUD Estrogen + Progesterone ! " Condom ! " Combined Oral Contraceptive Pills ! " Contraceptive Patch ! " Vaginal Ring
    [Show full text]
  • Emergency Contraceptives Rao 2019
    DRUG PROFILE Emergency Contraceptives CHANDRIKA RAO1 AND NIMRAT SANDHU1 From 1Department of Paediatrics, MS Ramaiah Medical College, Bangalore, Karnataka Correspondence: Dr Chandrika Rao, Professor, Department of Paediatrics, MS Ramaiah Medical College, Bangalore, Karnataka, India. [email protected] Emergency contraceptives are indicated in adolescents as an 'emergency' birth control method after sexual assault or an unprotected intercourse or failure of 'routine' method of contraception. It does not protect against sexually transmitted infections or future pregnancies, when usual birth control methods are not used. It has few side effects and follow up visits are indicated in specific circumstances. Key words: emergency contraceptives, pregnancy Contraception is the deliberate use of artificial methods or other previous pill; techniques to prevent pregnancy as a consequence of sexual intercourse. o Dislodgment, breakage, tearing, or early removal of a diaphragm or The major forms of artificial contraception are the barrier methods, the contraceptive pill and intrauterine devices and sterilisation. cervical cap; o EMERGENCY CONTRACEPTION Failed withdrawal Emergency contraception (EC) refers to methods that can be used to o Failure of a spermicide tablet or film to melt before intercourse; prevent pregnancy after sexual intercourse. These are recommended for o Miscalculation of the abstinence period, or use within 5 days of the intercourse. They are more effective, if they are o Expulsion of an IUD or hormonal contraceptive implant. used soon after intercourse. EC can prevent up to over 95% of pregnancies when taken within 5 days after intercourse. MECHANISM OF ACTION Intra Uterine device (IUD)s are considered the most effective form of Oral emergency contraceptives work primarily by delaying ovulation.
    [Show full text]